Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 5/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30294077 | 0.92 | TFPI (0.61) | TFPIRXFP1VIPR1 | |
| SCHEMBL31461875 | 0.89 | TFPI (0.54) | TFPIKISS1ROPRM1OPRD1OPRK1 | |
| SCHEMBL29387006 | 0.89 | TFPI (0.65) | TFPIPTH1RRXFP1VIPR1 | |
| SCHEMBL31462043 | 0.89 | KISS1R (0.53) | TFPIPTH1RKISS1ROPRM1OPRD1 | |
| SCHEMBL31462110 | 0.88 | QRFPR (0.55) | TFPIPTH1RKISS1ROPRM1OPRD1 | |
| SCHEMBL31461897 | 0.88 | TFPI (0.53) | TFPIKISS1ROPRM1OPRD1OPRK1 | |
| SCHEMBL31332426 | 0.88 | PTH1R (0.54) | TFPIPTH1RVIPR1 | |
| SCHEMBL31462020 | 0.88 | OPRM1 (0.55) | TFPIKISS1ROPRM1OPRD1OPRK1 | |
| SCHEMBL29519384 | 0.88 | TFPI (0.68) | TFPIPTH1RVIPR1 | |
| SCHEMBL31332037 | 0.88 | TFPI (0.55) | TFPIPTH1RRXFP1VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116601290-A | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use | 普渡研究基金会 | 2023-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | TFPI 1593/4885PTH1R 4342/4885RXFP1 3960/4885 |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | TFPI 1593/4885PTH1R 4342/4885RXFP1 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.